Compare GDO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDO | EQ |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 57.8M |
| IPO Year | N/A | 2018 |
| Metric | GDO | EQ |
|---|---|---|
| Price | $11.73 | $0.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 39.4K | ★ 433.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.21 | $0.27 |
| 52 Week High | $13.04 | $2.35 |
| Indicator | GDO | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 35.50 |
| Support Level | $11.62 | $0.81 |
| Resistance Level | $11.78 | $0.92 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 93.75 | 10.98 |
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.